CN101065382A - 用于治疗炎性疾病的被取代的蝶啶类 - Google Patents

用于治疗炎性疾病的被取代的蝶啶类 Download PDF

Info

Publication number
CN101065382A
CN101065382A CNA2005800408289A CN200580040828A CN101065382A CN 101065382 A CN101065382 A CN 101065382A CN A2005800408289 A CNA2005800408289 A CN A2005800408289A CN 200580040828 A CN200580040828 A CN 200580040828A CN 101065382 A CN101065382 A CN 101065382A
Authority
CN
China
Prior art keywords
alkyl
expression
nitrogen
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800408289A
Other languages
English (en)
Chinese (zh)
Inventor
多米尼克·马蒂雷斯
于尔根·麦克
霍斯特·多林格
彼得·尼科劳斯
伯吉特·琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101065382A publication Critical patent/CN101065382A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800408289A 2004-11-29 2005-11-25 用于治疗炎性疾病的被取代的蝶啶类 Pending CN101065382A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057618A DE102004057618A1 (de) 2004-11-29 2004-11-29 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618.1 2004-11-29

Publications (1)

Publication Number Publication Date
CN101065382A true CN101065382A (zh) 2007-10-31

Family

ID=35789067

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800408289A Pending CN101065382A (zh) 2004-11-29 2005-11-25 用于治疗炎性疾病的被取代的蝶啶类

Country Status (17)

Country Link
US (1) US7550472B2 (https=)
EP (1) EP1828189A1 (https=)
JP (1) JP2008521775A (https=)
KR (1) KR20070090975A (https=)
CN (1) CN101065382A (https=)
AR (1) AR054992A1 (https=)
AU (1) AU2005308785A1 (https=)
BR (1) BRPI0516626A (https=)
CA (1) CA2589209A1 (https=)
DE (1) DE102004057618A1 (https=)
IL (2) IL183447A0 (https=)
MX (1) MX2007006357A (https=)
NZ (1) NZ556152A (https=)
RU (1) RU2007124328A (https=)
TW (1) TW200633711A (https=)
WO (1) WO2006056607A1 (https=)
ZA (1) ZA200703125B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022000708A1 (zh) * 2020-07-01 2022-01-06 广州华真医药科技有限公司 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
CA2652840C (en) 2006-05-24 2014-09-09 Boehringer Ingelheim International Gmbh 2-piperazino-6-chloro-pteridines as pde4-inhibitors for the treatment of inflammatory diseases
WO2007146087A2 (en) * 2006-06-06 2007-12-21 Avigen, Inc. SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
ES3041129T3 (en) 2017-10-23 2025-11-07 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EP4520394A3 (en) 2021-12-09 2025-04-02 Boehringer Ingelheim International GmbH New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
FI4426307T3 (fi) 2021-12-09 2025-09-10 Boehringer Ingelheim Int Uusi suun kautta otettava farmaseuttinen koostumus ja annosteluohjelma progressiivisen interstitiaalisen keuhkosairauden hoitoon
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
DE3323932A1 (de) 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3540952C2 (de) 1985-11-19 1997-08-14 Thomae Gmbh Dr K 2-Piperazino-pteridine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2229803T3 (es) 1998-12-28 2005-04-16 4 Aza Bioscience Nv Efectos inmunosupresivos de derivados de pteridina.
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE10202468A1 (de) * 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022000708A1 (zh) * 2020-07-01 2022-01-06 广州华真医药科技有限公司 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用

Also Published As

Publication number Publication date
WO2006056607A8 (de) 2007-01-18
IL183447A0 (en) 2007-09-20
CA2589209A1 (en) 2006-06-01
DE102004057618A1 (de) 2006-06-01
JP2008521775A (ja) 2008-06-26
AR054992A1 (es) 2007-08-01
KR20070090975A (ko) 2007-09-06
TW200633711A (en) 2006-10-01
NZ556152A (en) 2009-06-26
IL209879A0 (en) 2011-02-28
MX2007006357A (es) 2007-06-20
RU2007124328A (ru) 2009-02-20
WO2006056607A1 (de) 2006-06-01
AU2005308785A1 (en) 2006-06-01
ZA200703125B (en) 2008-09-25
US7550472B2 (en) 2009-06-23
BRPI0516626A (pt) 2008-09-16
EP1828189A1 (de) 2007-09-05
US20060116372A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
CN1094490C (zh) 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物
CN1555374A (zh) 新的吡啶取代的吡唑并吡啶衍生物
US20100234347A1 (en) Substituted Pteridines substituted with a Four-Membered Heterocycle
CN1104422C (zh) 用作α－2肾上腺素能受体兴奋剂的胍基杂环化合物
CN1186492A (zh) 咪唑并[1,2－α]吡啶衍生物
CN1306533A (zh) 抑制胃酸分泌的咪唑并吡啶衍生物
CN101065382A (zh) 用于治疗炎性疾病的被取代的蝶啶类
CN1331076A (zh) 稠合的吡唑基化合物、包含该化合物的组合物及该化合物的应用
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1224624C (zh) 1,8－二氮杂萘－2(1h)－酮衍生物
CN1238771A (zh) 用作α－2肾上腺素能受体兴奋剂的2－咪唑啉基氨基吲哚化合物
CN1144802A (zh) 哒嗪酮衍生物及其制备方法
CN1309642A (zh) 具有止喘、抗变态反应、抗炎、免疫调节和神经保护作用的新的1,2,5－三取代1,2－二氢吲唑－3－酮类化合物、其制备方法以及作为药物的应用
CN1966506A (zh) 吡唑并嘧啶酮衍生物及其制备方法和用途
CN1774250A (zh) 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6－(苯氧基)－吡啶并[3,4－d]嘧啶－2－基)－胺衍生物
CN87104641A (zh) 4-(芳酰氨基)哌啶丁酰氨衍生物
CN1266134C (zh) 稠合多环化合物
CN1126738C (zh) 苯甲酰胺衍生物及含有它们的药物
CN1860119A (zh) 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
CN1665508A (zh) 吡唑并[4,3－d]嘧啶类化合物的应用
CN1183115C (zh) 5-氨基-8-甲氧基喹诺酮羧酸类衍生物及其制法
CN1856491A (zh) 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物
HK1041819A1 (zh) Nos抑制剂的新药学用途
CN1990470A (zh) 酞丁安衍生物及其制法和其药物组合物与用途
CN1805960A (zh) 7－氮杂吲哚类化合物以及其用作治疗剂的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071031